Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Established
2001
Location
-, Hertfordshire, UK
Primary Industry
Biotechnology
About
Based in Melbourne, England, abd founded in 2001, SPT Labtech Limited, formerly known as TTP Labtech Limited, offers data driven solutions for life sciences applications such as drug discovery, molecular biology and genomics and structural biology to eliminate drug-discovery bottlenecks. In June 2022, EQT agreed to acquire SPT Labtech Limited from Battery Ventures for GBP 650 million. As of January 2024, David Newble is the Chief Executive Officer (CEO) of the company. SPT Labtech Limited has accelerated its research and development activities by working together, applying expertise, and utilizing technical solutions.
GlaxoSmithKline plc, Dart NeuroScience LLC, and Abcam plc are some of the notable partners. The company's product portfolio includes offerings such as Dragonfly Discovery, Dragonfly Crystal, Mosquito HV Genomics, Mosquito LV Genomics, Mosquito Xtal3, Mosquito (LCP, HV, LV, X1, and Crystal), Chameleon, Arktic XC, Arktic, comPOUND, and Lab2Lab, which benefit scientists, service teams, and budget holders. SPT Labtech utilized pneumatic technology to create a pharmaceutical research and development instrument capable of sorting, storing, and transporting samples. Additionally, the organization uses positive displacement pipetting for liquid handling.
Additionally, SPT Labtech offers an automated online analysis solution that incorporates Nanoscale chemistry to improve drug discovery research. The company also provides technical support and instrument relocation services, which include pre-inspection, decommissioning, transportation, reinstallation, and testing of instruments. SPT Labtech provides application support services such as annual preventive maintenance, phone and email assistance, remote access support, application software updates, user training, and performance optimization sessions.
Biotechnology
Biopharmaceuticals, Diagnostic, Medical & Imaging Laboratories
www.sptlabtech.com
Mature

| Fiscal Year Ended | Mar 31, 2011 | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 11,370,000 | 11,869,000 | 12,125,000 | 17,446,000 | 18,035,000 | 19,176,000 | 21,477,000 | 24,422,000 | 25,527,000 | 31,508,000 | 30,704,000 | 47,841,000 | - | - | - |
| % Revenue Growth (YoY) | - | 4.4% | 2.2% | 43.9% | 3.4% | 6.3% | 12.0% | 13.7% | 4.5% | 23.4% | - | - | - | - | - |
| EBITDA (USD) | (1,042,000) | (449,000) | (860,000) | 1,113,000 | 343,000 | (1,550,000) | (440,000) | (36,000) | 798,000 | 5,660,000 | 11,241,000 | 15,410,000 | - | - | - |
| Operating Income (USD) | (1,480,000) | (947,000) | (1,235,000) | 803,000 | (9,000) | (1,901,000) | (805,000) | (687,000) | 229,000 | 5,087,000 | 10,781,000 | 14,637,000 | - | - | - |
| Operating Margin | (13.0%) | (8.0%) | (10.2%) | 4.6% | (0.0%) | (9.9%) | (3.7%) | (2.8%) | 0.9% | 16.1% | 35.1% | 30.6% | - | - | - |
| % EBITDA Margin | (9.2%) | (3.8%) | (7.1%) | 6.4% | 1.9% | (8.1%) | (2.0%) | (0.1%) | 3.1% | 18.0% | 36.6% | 32.2% | - | - | - |
| NET Income (USD) | (1,438,000) | (979,000) | (285,000) | 833,000 | 65,000 | (2,046,000) | (1,021,000) | (881,000) | 68,000 | 4,353,000 | 8,455,000 | 12,428,000 | - | - | - |
| % Net Margin | (12.6%) | (8.2%) | (2.4%) | 4.8% | 0.4% | (10.7%) | (4.8%) | (3.6%) | 0.3% | 13.8% | 27.5% | 26.0% | - | - | - |
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Secondary Buyout | Completed | SPT Labtech Limited | - | ||||||||
| Add-on | Completed | BioMicroLab, Inc. | - | ||||||||
| Add-on | Completed | Apricot Designs, Inc. | - | ||||||||
| Buyout | Completed | SPT Labtech Limited | - |
Displaying 1 - 4 of 4
